3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor
1
Rectal Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced Cervical Cancer
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Carcinoid Tumor
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
Radiotherapy
3
pembrolizumab
2
fludarabine
2
Drug Therapy
2
Cyclophosphamide
2
zimberelimab
1
lenvatinib
1
envafolimab
1
Thymectomy
1
Thoracic Surgery, Video-Assisted
1
Radiotherapy, Adjuvant
1
Proton Therapy
1
Paclitaxel
1
Methylprednisolone
1
Immunotherapy
1
Heavy Ion Radiotherapy
1
Carboplatin
1
Bupivacaine
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thymoma
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled